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Abstract 
Ultraviolet A photosensitivity is a debilitating symptom associated with the metabolic disorder Smith-Lemli-Opitz syndrome 
(SLOS). SLOS is a manifestation of the deficiency of 7-dehydrocholesterol reductase, an enzyme involved in the cholesterol 
biosynthesis.  As a result several abnormal intermediary compounds are formed among which cholesta 5, 7, 9(11)-trien-3beta-
ol is the most likely cause of photosensitivity. The effect of various drugs acting on cholesterol biosynthetic pathway on SLOS 
is not clear as clinical trials are not available for this rare disorder. A Flux Balance Analysis (FBA) has been carried out using 
the software CellNetAnalyzer or FluxAnalyzer to gain insight into the probable effects of various drugs acting on cholesterol 
biosynthetic pathway on photosensitivity in SLOS. The model consisted of 44 metabolites and 40 reactions. The formation 
flux of cholesta 5, 7, 9(11) - trien-3beta-ol increased in SLOS and remained unchanged on simulation of the effect of 
miconazole and SR31747. However zaragozic acid can potentially reduce the flux through the entire pathway. FBA predicts 
zaragozic acid along with cholesterol supplementation as an effective treatment for photosensitivity in SLOS. 
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Background: 
The Smith-Lemli-Opitz syndrome (SLOS) is a rare 
autosomal recessive disorder characterised by multiple 
congenital abnormalities. [1, 2] SLOS is a manifestation of 
an abnormality in the late phase of cholesterol biosynthesis 
due to an inherited deficiency of the enzyme 7-
dehydrocholesterol-reductase [3]. It is caused by mutations 
in the DHCR7 gene coding for 7-dehydrocholesterol-
reductase. [4]  
  
As cholesterol is an important cell membrane constituent 
and a precursor of several important hormones, the clinical 
expression is diverse, ranging from facial dismorphism to 
limb and major organ defects. [3] However dermatologists 
are especially interested in the photosensitivity associated 
with SLOS which was unfortunately missed in the early 
reports of this syndrome. The first detailed report of 
photosensitivity occurred only in 1998  [5] and SLOS is 
now considered as the primary inherited photosensitivity 
syndrome with photosensitivity to Ultraviolet A. [6] The 
pattern of photosensitivity is also quite distinct with onset 
within minutes of sun exposure, sunburn-like erythema 
lasting for 24-36 hours and an action spectrum with a peak 
at 350 nm. [7] 
 
Though the final stages of cholesterol biosynthesis are 
adequately described  [8], the metabolic fate of 7-
dehydrocholesterol (7-DHC) which accumulates as a result 
of the deficiency of its reductase enzyme in SLOS is 
unclear. Major C27 sterols observed in SLOS patients apart 
from cholesterol and 7-DHC are 8-dehydrocholesterol (8-
DHC) and cholesta-5,7,9(11)-trien-3β-ol. [9] Cholesta-
5,7,9(11)-trien-3β-ol is formed by oxidation of 7-DHC   
[10] and 8-DHC is formed by reverse isomerization of 7-
DHC at the Δ5,7 level.  [11] There has also been a report of 
the presence of an aromatic triene, 19-nor-5,7,9(10)-
cholesta-trien-3β-ol [12] which can be considered an 
artefact.  [9] It has recently been proved that among these 
aberrant metabolites, Cholesta-5,7,9(11)-trien-3β-ol is the 
most likely cause of Ultraviolet A photosensitivity. [1] 
Hence UVA photosensitivity is a symptom not directly 
related to deficiency of cholesterol.  
 
Though cholesterol supplementation is found to be useful 
in relieving photosensitivity  [6], the effect of other drugs 
which act on the final phase of cholesterol biosynthesis on 
this symptom is unknown. Among the several 
computational methods available for metabolic simulation, 
Flux Balance Analysis (FBA) will be appropriate for 
modelling this pathway as the detailed kinetic information 
is not available for all enzymes involved and more than one 
pathway exist to transform precursors to cholesterol  [13] 
though it has traditionally been used to quantitatively 
simulate microbial metabolism.  [14]  FBA involves 
prediction of metabolic flux distribution based on 
stoichiometric, thermodynamic and reaction capacity 
constraints. FBA has been used here to understand the 
behaviour of the final stages of cholesterol biosynthesis in 
normal and SLOS individuals and to gain insight into the 
probable effects of drugs acting on this pathway on the 
symptom of photosensitivity. 
 
Methodology: 
FBA is a stoichiometric analysis technique used to model 
cellular behaviour in the absence of detailed kinetic 
information. [13] It is also useful in situations where an 
optimal flux distribution analysis is enough to generate 
quantitative hypotheses that may be tested experimentally 
as in SLOS.  
 
A model of the final stages of cholesterol biosynthesis from 
the condensation of two molecules of farnesyl 
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CellNetAnalyzer / FluxAnalyzer.  [15] It is a MATLAB ® 
package for interactive network analysis.  
 
The first nine reactions of cholesterol biosynthesis 
encompasses the mevalonate pathway which is common for 
several classes of compounds in addition to cholesterol.   
[16] The mevalonate pathway is highly regulated especially 
by feedback inhibition of HMG-CoA reductase by 
cholesterol and 7 DHC  [17]. FBA is essentially an analysis 
of steady state and cannot adequately represent a feedback 
regulated or shared network. Hence these reactions were 
excluded from the model. 
 
7-DHC has four metabolic fates apart from its conversion 
to cholesterol. Conversion to Vitamin D in the skin  [18], 
Isomerization to 8-DHC  [11], Oxidation to cholesta-
5,7,9(11)-trien-3β-ol   [10] and 19-nor-5,7,9(10)-cholesta-
trien-3β-ol   [12]. The flux through the formation of 
cholesta-5,7,9(11)-trien-3β-ol is important for 
photosensitivity. 
 
The Biocyc repository of pathway models  [19] provided 
the basic framework for the model. The metabolites and 
reactions are represented in Table 1 and Table 2 
respectively (supplementary material). The minimum 
reaction rate is set to 0 for irreversible reactions and -1 for 
reversible reactions. The maximum rate was set to unity for 
all reactions, so that the model will provide the relative 
ratios of fluxes. The coefficient of objective function was 
also set to zero. 
 
The imposition of these constraints resulted in a bounded 
solution space wherein every possible flux distribution 
must lie and an optimal metabolic flux distribution was 
calculated by the software using linear programming. 
 
The loss of gene function in SLOS and enzyme inhibition 
by drugs are simulated by restricting the maximum flux 
through a particular reaction to a small value of 0.01. The 
flux through the input arm of the model (R1) was kept at 
the maximum possible value of one except for drugs 
blocking squalene synthase (R2) as the model will not be 
feasible. 19-nor-5,7,9(10)-cholesta-trien-3β-ol is now 
considered an artifact in fractions containing 8-
dehydrocholesterol. [9] Hence the maximum flux through 
R36 which represents the formation of 19-nor-5,7,9(10)-
cholesta-trien-3β-ol was also set to 0.01. 
 
The effects of four groups of drugs were modelled. 
AY9944 and BM15766 class of compounds acting on 7-
dehydrocholesterol reductase  [20] thereby simulating 
SLOS (R22 and R26), Miconazole and related compounds 
acting on 14-α demethylase  [21] in SLOS patients (R5 + 
R22 and R26), zaragozic acid and related compounds  [22] 
interfering with Squalene Synthase (R2 + R22 and R26) 
and SR31747 group of compounds  [23] inhibiting Δ8-Δ7 
sterol isomerase (R39 + R22 and R26).  
 
The optimal flux distribution was calculated after 
simulating the effect of each drug as mentioned above and 
the flux through the formation of cholesta-5,7,9(11)-trien-
3β-ol which is important in photosensitivity was compared. 
 
 
Results: 
The model of the final phase of cholesterol synthesis built 
consisted of 44 metabolites (Table 1 in supplementary 
material) and 40 reactions (Table 2 in supplementary 
material). The relative flux distribution of the model is 
shown in (Figure 1).  The flux through R 37 which 
represents the formation of cholesta-5,7,9(11)-trien-3β-ol 
will be indicative of the severity of photosensitivity. The 
inhibition of R22 and R26 as in SLOS resulted in doubling 
of flux through R37 from 0.2 to 0.49. There was no 
apparent change after blockage of R5 and R39 which 
simulates miconazole and SR31747 administration. 
However inhibition of R2 as in zaragozic acid 
administration resulted in the decline of flux through the 
entire pathway including R37 to almost zero.  
 
Discussion: 
The UVA photosensitivity in SLOS could be severe in 
some patients and the first detailed description of SLOS 
associated photosensitivity in a five-year-old girl describes 
how her parents tried to protect her from light by making a 
one-piece photoprotection suit with small openings for the 
eyes and mouth.  [5] However there are not many studies 
on the management of this symptom even at this time. 
 
The first clinical trial on SLOS patients was for cholesterol 
supplementation and reported only subjective improvement 
in photosensitivity [24] which was corroborated by another 
study. [25] Though HMG-CoA inhibitor simvastatin along 
with cholesterol supplementation suppresses most of the 
symptoms of SLOS  [26] there is no specific mention of its 
effect in photosensitivity except for a remark in a review. 
[6] Though the effect of feedback control of cholesterol on 
HMG-CoA reductase and the inhibition of the same 
enzyme by simvastatin is not directly apparent from our 
model, both can potentially reduce the flux through the 
input arm of the model (R1) thereby reducing the overall 
flux. 
 
As per the model, the flux through R5 (14α-demethylation) 
is much greater than R28 (anaerobic reduction involving 
Δ24-reductase) which has the support of experimental 
evidence [21].Miconazole and ketoconazole are frequently 
used azole antifungals, which inhibit the 14α-methyl 
demethylase enzyme, catalysing the preferred route for 
conversion of lanosterol to cholesterol. However there is no 
significant effect for these drugs on the terminal pathway as 
the alternate route involving Δ24-reductase gets activated. 
[21] 
 
SR31747 is a novel immunosuppressive agent and an 
inhibitor of Δ8-Δ7 sterol isomerase. Tamoxifen is a 
commonly used antiestrogen inhibiting the same enzyme. 
The effects of both this drugs were simulated by blocking 
the reversible reaction (R39) which did not alter the flux 
distribution.  
 
Zaragozic acid is a naturally occurring squalene synthase 
inhibitor, which has attracted attention because of its 
cholesterol lowering properties. [22] As this compound acts 
on R2, before the beginning of alternate pathways, it can 
potentially reduce the flux through the entire network 
including C37 important for photosensitivity.  Hence 
zaragozic acid derivatives along with cholesterol Bioinformation by Biomedical Informatics Publishing Group                   open access 
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supplementation could be very effective in the management  of photosensitivity in SLOS.
   
Figure 1: Relative flux distribution 
 
Conclusion: 
FBA has been used for several years to study cellular 
metabolism with high network connectivity and 
redundancy. It has also been used previously to identify 
probable drug targets. [27] This study demonstrates its use 
in the analysis of the effect of various drugs on an 
individual symptom of a metabolic disorder. Though 
reliability of FBA for a specific pathway is debatable, it 
provides some insight into the possible effect of certain 
well known drugs on photosensitivity, which needs to be 
clinically verified. 
 
Resources: 
The model prepared in CellNetAnalyzer is available from 
[28]. Other resources including the model in SBML format 
and the reactions as a flat file are available from [29]. 
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Supplementary material 
 
SQ  squalene 
ESQ  2,3-Epoxysqualene 
H2O  Water 
O2  Oxygen 
NADP  NADP 
NADPH  NADPH 
FORMATE  FORMATE 
CO2  Carbon Dioxide 
LA    Lanosterol 
C_8_24_DIEN  4,4-dimethyl-14a-hydroxymethyl-5a-cholesta-0,24-dien-3b-ol 
F_C_8_24_DIEN  4,4-dimethyl-14a-formyl-5a-cholesta-8,24-dien-3b-ol 
C_8_14_24_TRIEN  4,4-dimethyl-5-a-cholesta-8,14,24-trien-3-b-ol 
C5_8_24_DIEN   4,4-dimethyl-5a-cholesta-8,24-dien-3-b-ol 
HMC_8_24_DIEN  4a-hydroxymethyl-4b-methyl-5a-cholesta-8,24-dien-3b-ol 
FMC_8_24_DIEN    4a-fonnyl-4b-methyl-5a-cholesta-8,24-dien-3b-ol 
CMC_8_24_DIEN    4a-carboxy-4b-methyl-5a-cholesta-8,24-dien-3b-ol 
MC_8_24_DIEN_ON  4a-methyl-5a-cholesta-8,24-dien-3-one 
MZ  4-a-methyl-zymosterol 
MC4_8_24_DIEN  4a-hydroxymethyl-5a-cholesta-8,24-dien-3b-ol 
FC_8_24_DIEN  4a-formyl-5a-cholesta-8,24-dien-3b-ol 
CC_8_24_DIEN   4a-carboxy-5a-cholesta-8,24-dien-3b-ol 
C5_8_24_DIEN_ON  5a-cholesta-8,24-dien-3-one 
Z  zymosterol 
C_7_24_DIEN  5a-cholesta-7,24-dien-3b-ol 
L  lathosterol 
DHC7  7-dehydro-cholesterol 
C  cholesterol 
CYA   cycloartenol 
DHD7  7-dehydro-desmosterol 
D  desmosterol 
DHL  24,25-dihydro-lanosterol 
EN_8  4-a-methylcholesta-8-en-3b-ol 
M  mestenol 
E  Ergosterol 
P  Phytosterol 
DHC8  8-dehydro-cholesterol 
EN8OL   cholesta-8-en-3b-ol 
TRIEN_11  D-5,7,9(11)-trien 
H2O2  Hydrogen Peroxide 
NOR_10_19    d5,7,9(10)trien-nor 
VITD3  vitd3 
FDP  2-trans,trans-farnesyl-diphosphate 
PSQ  presqualene-diphosphate 
DIPHOSPHATE   diphosphate 
Table 1: List of metabolites in the model 
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R1  2 FDP ==> PSQ + DIPHOSPHATE 
R2  NADPH + PSQ ==> SQ + NADP + DIPHOSPHATE 
R3  SQ + O2 + NADPH ==> ESQ + H2O + NADP 
R4  ESQ ==> LA 
R5   O2 + NADPH + LA ==> H2O + NADP + C_8_24_DIEN 
R6  O2 + NADPH + C_8_24_DIEN ==> 2 H2O + NADP + F_C_8_24_DIEN 
R7  O2 + NADPH + F_C_8_24_DIEN ==> H2O + NADP + FORMATE + C_8_14_24_TRIEN 
R8  NADPH + C_8_14_24_TRIEN ==> NADP + C5_8_24_DIEN 
R9  O2 + NADPH + C5_8_24_DIEN ==> H2O + NADP + HMC_8_24_DIEN 
R10  O2 + NADPH + HMC_8_24_DIEN ==> 2 H2O + NADP + FMC_8_24_DIEN 
R11  O2 + NADPH + FMC_8_24_DIEN ==> H2O + NADP + CMC_8_24_DIEN 
R12  NADP + CMC_8_24_DIEN ==> NADPH + CO2 + MC_8_24_DIEN_ON 
R13  NADPH + MC_8_24_DIEN_ON ==> NADP + MZ 
R14   O2 + NADPH + MZ ==> H2O + NADP + MC4_8_24_DIEN 
R15  O2 + NADPH + MC4_8_24_DIEN ==> 2 H2O + NADP + FC_8_24_DIEN 
R16  O2 + NADPH + FC_8_24_DIEN ==> H2O + NADP + CC_8_24_DIEN 
R17  NADP + CC_8_24_DIEN ==> NADPH + CO2 + C5_8_24_DIEN_ON 
R18  NADPH + C5_8_24_DIEN_ON ==> NADP + Z 
R19  Z ==> C_7_24_DIEN 
R20  NADPH + C_7_24_DIEN ==> NADP + L 
R21  O2 + NADPH + L ==> H2O + NADP + DHC7 
R22   NADPH + DHC7 ==> NADP + C 
R23  ESQ ==> CYA 
R24  CYA ==> Z 
R25  C_7_24_DIEN ==> DHD7 
R26  DHD7 ==> D 
R27  D ==> C 
R28  LA ==> DHL 
R29  C_8_24_DIEN ==> EN_8 
R30  DHL ==> EN_8 
R31  EN_8 ==> M 
R32  M ==> L 
R33  D ==> E 
R34  D ==> P 
R35  DHC7 <==> DHC8 
R36  DHC7 ==> NOR_10_19 
R37  O2 + DHC7 ==> TRIEN_11 + H2O2 
R38  DHC7 ==> VITD3 
R39  L <==> EN8OL 
R40  EN8OL ==> DHC8 
Table 2: List of reactions in the model 
 